Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Breast Cancer

Breast cancer is the most common non-skin cancer among women. The chance of developing invasive breast cancer at some point in a women's life is about 1 in 8 or 13% of women. It is estimated that in 2007 about 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Stryker Orthopaedics, ... and Champions Tour, is rounding out its debut year ... in Scottsdale, AZ. This marks ... and Champions Tour that the brand has activated on-site ... to educate golf fans on the importance of joint ...
(Date:10/30/2014)... SHANGHAI , Oct. 30, 2014 WuXi PharmaTech ... open-access R&D capability and technology platform company serving the ... China and the ... a representative office in the Tel Aviv ... new office will promote WuXi,s broad platform of integrated ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2
... 11, 2011 U LURUInc.(NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... (the "Exchange") advising ULURU that it is not in compliance ... under Section 1003 of the Exchange,s Company Guide (the "Company ...
... March 11, 2011 Mylan Inc. (Nasdaq: ... has upgraded the company,s credit ratings, including the "Corporate ... this action, Moody,s rating outlook is stable.   ... improving earnings trends accomplished through new product launches, a ...
Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2Moody's Upgrades Mylan 2
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Scientists who used stem ... say their breakthrough could provide a new way to ... diseases. The team used human pluripotent stem cells ... the body -- to grow the functional miniature stomachs, ... a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... milk could be bad for your health, a new study ... milk can help strengthen bones and prevent osteoporosis. These benefits ... milk as part of a healthy diet. But this ... not protect men or women from bone fractures, and was ...
(Date:10/30/2014)... (HealthDay News) -- Eating a low-carb, high-fat diet could ... to new research. A review of five ... that focuses on foods like bacon, eggs, heavy cream, ... in adults whose condition doesn,t improve with medication. ... people with epilepsy whose seizures are not stopped by ...
(Date:10/30/2014)... News) -- A new vaccine that could help prevent ... by the U.S. Food and Drug Administration on Wednesday. ... ages of 10 and 25 from invasive meningococcal disease ... The bacteria can infect the bloodstream (sepsis) and ... It is a leading cause of bacterial meningitis, and ...
(Date:10/30/2014)... – A new standard of care for children facing ... multi-year study published in the latest edition of the ... research, led by John Wagner, Jr., M.D., director of ... University of Minnesota and a researcher in the Masonic ... with acute leukemia and myelodysplastic syndrome who received transplants ...
Breaking Medicine News(10 mins):Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3
... was true for males tying the knot with younger females, study ... men seven to nine years their junior could be upping their ... with a significantly younger guy raises a woman,s risk of death ... 12 issue of Demography . , Not that marrying much ...
... years ago, scientists at Beth Israel Deaconess Medical Center ... the Akt molecular pathway, a popular target for cancer ... Akt1 was actively preventing cancer cells from ... was actually promoting breast cancer cell migration. And, indeed, ...
... 22q11 deletion syndrome (also known as DiGeorge syndrome) ... having an estimated incidence of at least one ... of severity but a multisystem impact, with symptoms ... endocrine abnormalities, cleft palate, gastrointestinal problems, and neuropsychiatric ...
... National ... was recently awarded certification from the Women’s Business Enterprise National Council (WBENC). ... San Diego, CA ... provider of water conservation and water management services , was ...
... ... extension option with Novation the leading health care supply contracting company for more than 25,000 ... and nearly 15,000 members of Provista, LLC. , ... Santa Clara (Vocus) May 14, 2010 -- Lumenis Ltd., a global leader ...
... out of ten patients who discontinued their overactive bladder (OAB) ... or they couldn,t tolerate it, according to research in the ... US researchers also discovered that smokers, men with enlarged prostates ... to stop taking prescription drugs for bladder problems. The ...
Cached Medicine News:Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:Without this protein, embryonic development halts 2Health News:National Water Services, Inc. Receives WBE Certification 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 2Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 3Health News:Lumenis Inc. Awarded a 3-year Dual Source Agreement with Novation 4Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 2Health News:Unmet expectations and smoking prove key factors in quitting bladder medication 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: